Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBT (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed EBT for 16 consecutive years, with -$38.0 million as the latest value for Q4 2025.

  • Quarterly EBT fell 484.92% to -$38.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$138.6 million through Dec 2025, down 504.89% year-over-year, with the annual reading at -$138.6 million for FY2025, 504.89% down from the prior year.
  • EBT hit -$38.0 million in Q4 2025 for Vanda Pharmaceuticals, down from -$28.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $12.6 million in Q2 2021 to a low of -$38.0 million in Q4 2025.
  • Historically, EBT has averaged -$5.1 million across 5 years, with a median of -$890500.0 in 2023.
  • Biggest five-year swings in EBT: skyrocketed 740.29% in 2021 and later tumbled 5103.33% in 2024.
  • Year by year, EBT stood at $8.6 million in 2021, then increased by 11.65% to $9.6 million in 2022, then crashed by 117.28% to -$1.7 million in 2023, then crashed by 291.15% to -$6.5 million in 2024, then plummeted by 484.92% to -$38.0 million in 2025.
  • Business Quant data shows EBT for VNDA at -$38.0 million in Q4 2025, -$28.4 million in Q3 2025, and -$34.9 million in Q2 2025.